Rush Introduces Bill to Raise Awareness of Depression Side Effects
WASHINGTON — Today, U.S. Representative Bobby L. Rush (D-Ill.) introduced H.R. 6717, the ‘‘Depression Side Effect Labeling Awareness Act of 2018.’’ This legislation would amend the Federal Food, Drug, and Cosmetic Act and require that drugs with an increased risk of suicide or depression have a prominent label detailing those side effects.
“There are millions of Americans who are taking prescribed and over the counter medication that can greatly increase the risk of suicide or depression. Therefore, it is critically important that those risk factors are prominently displayed to ensure that patients along with their health care provider can have a more thorough discussion as it relates to patient safety and awareness of harmful side effects,” said Rush.
This legislation would amend the end of Section 502 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352) 6 and add: ‘‘(ee) If the warnings and precautions in the drug’s label include an increased risk of suicide or depression, unless such increased risk is presented prominently.’’
“A paper published this summer by the Journal of the American Medical Association showed that prescription medications are increasingly used among adults in the United States and many have a potential for causing depression. As legislators we must use our power to provide awareness and inform Americans about the medications they are taking and how it can affect their lives.”